174 related articles for article (PubMed ID: 2170552)
1. Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
Yamaguchi K; Nishimura Y; Kiyokawa T; Matsuzaki H; Ishii T; Kubota K; Kawahara M; Furuse K; Yoshinaga T; Kinuwaki E
J Lab Clin Med; 1990 Oct; 116(4):457-61. PubMed ID: 2170552
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
4. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.
Tisi E; Lissoni P; Angeli M; Arrigoni C; Corno E; Cassina E; Ballabio D; Benenti C; Barni S; Tancini G
Cancer; 1992 May; 69(10):2458-62. PubMed ID: 1314691
[TBL] [Abstract][Full Text] [Related]
5. Elevated concentration of soluble interleukin-2 receptors in serum of smokers and patients with lung cancer. Correlation with clinical activity.
Ginns LC; De Hoyos A; Brown MC; Gaumond BR
Am Rev Respir Dis; 1990 Aug; 142(2):398-402. PubMed ID: 2200317
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
7. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
[TBL] [Abstract][Full Text] [Related]
8. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
[TBL] [Abstract][Full Text] [Related]
9. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of serum soluble interleukin-2 receptors in lung cancer.
Yano T; Yoshino I; Yokoyama H; Fukuyama Y; Takai E; Asoh H; Ichinose Y
Lung Cancer; 1996 Aug; 15(1):79-84. PubMed ID: 8865125
[TBL] [Abstract][Full Text] [Related]
11. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptors (sIL-2R) and neuron specific enolase (NSE) in small cell lung carcinoma.
Sarandakou A; Poulakis N; Rizos D; Trakakis E; Phocas I
Anticancer Res; 1993; 13(1):173-5. PubMed ID: 8386493
[TBL] [Abstract][Full Text] [Related]
14. Soluble interleukin-2 receptor as a clinical parameter for nasopharyngeal carcinoma.
Hsu MM; Chen YJ; Chang YL; Ko JY; Sheen TS
Asian Pac J Allergy Immunol; 1995 Jun; 13(1):1-4. PubMed ID: 7488337
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
16. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
18. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer.
Katoh R; Takenoshita S; Shimizu Y; Tanaka S; Yajima Y; Nagamachi Y
Anticancer Res; 1997; 17(5B):3787-92. PubMed ID: 9427781
[TBL] [Abstract][Full Text] [Related]
20. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]